Agents effective against mania in bipolar disorder are reported to decrease turnover of arachidonic acid (AA) in phospholipids and expression of calcium-dependent AA-selective cytosolic phospholipase A 2 (cPLA 2 ) in rat brain. In contrast, fluoxetine, an antidepressant that is reported to switch bipolar depressed patients to mania, increases cPLA 2 expression and AA turnover in rat brain. We therefore hypothesized that antidepressants that increase switching to mania generally increase cPLA 2 and AA turnover in brain. To test this hypothesis, adult male CDF-344 rats were administered imipramine and bupropion, with reported high and low switching rates, respectively, at daily doses of 10 and 30 mg kg À1 i.p., respectively, or i.p. saline (control) for 21 days. Frontal cortex expression of different PLA 2 enzymes and AA turnover rates in brain when the rats were unanesthetized were measured. Compared with chronic saline, chronic imipramine but not bupropion significantly increased cortex cPLA 2 mRNA activity, protein and phosphorylation, expression of the cPLA 2 transcription factor, activator protein-2a (AP-2a) and AA turnover in phospholipids. Protein levels of secretory phospholipase A 2 , calcium-independent phospholipase A 2 , cyclooxygenase (COX)-1 and COX-2 were unchanged, and prostaglandin E 2 was unaffected. These results, taken with prior data on chronic fluoxetine in rats, suggest that antidepressants that increase the switching tendency of bipolar depressed patients to mania do so by increasing AA recycling and metabolism in brain. Mania in bipolar disorder thus may involve upregulated brain AA metabolism.
Introduction
Persons with bipolar disorder (BD) experience episodes of depression more frequently and for longer periods than episodes of mania.
1 Bipolar depression is a major cause of psychiatric morbidity and mortality and poses a major public health concern. A challenge in treating bipolar depression is the tendency of many antidepressants, particularly tricyclic antidepressants and serotonin selective reuptake inhibitors, to induce episodes of mania or to increase cycle frequency or symptom intensity. 2, 3 The causes for the tendency of antidepressants to 'switch' depressed bipolar patients to mania are not understood.
Antimanic mood stabilizers, lithium, valproic acid and carbamazepine, when given chronically to rats to produce plasma concentrations therapeutically relevant to BD, reduce arachidonic acid (AA; 20:4nÀ6) turnover in phospholipids and expression of AA cascade enzymes in rat brain. 4 AA is a polyunsaturated fatty acid found predominately in the stereospecifically numbered (sn)-2 position of membrane phospholipids, and can be released from this position by certain phospholipase A 2 (PLA 2 ) enzymes. 5 These enzymes can be activated through their coupling to certain neuroreceptors by a G-protein or by calcium, [6] [7] [8] [9] [10] or in conditions of neuroinflammation through their coupling to cytokine receptors. [11] [12] [13] The unesterified AA that is released by a PLA 2 can be converted to eicosanoids or other active metabolites, subjected to b-oxidation, or reesterified into the sn-2 position of membrane phospholipids via a long-chain acyl-CoA synthetase and an acyltransferase. [14] [15] [16] [17] [18] [19] Released AA and its metabolites can influence a number of brain processes, including signal transduction, transcription, neuronal activity, apoptosis, inflammation and blood flow. [20] [21] [22] [23] [24] [25] [26] The agents lithium, carbamazepine (5H-dibenz[b, f]azepine-5-carboxamide; 5-carbamoyl-5H-dibenz[b, f]azepine) and valproic acid (2-propylpentanoic acid), which are effective in the manic phase of BD, are reported to decrease brain AA turnover rate in membrane phospholipids in unanesthetized rats without changing the turnover rate of docosahexaenoic acid (DHA; 22:6nÀ3), [27] [28] [29] [30] [31] another polyunsaturated fatty acid usually found in the sn-2 position. The effect of chronically administered lithium and carbamazepine on AA turnover was ascribed to a selective decrease in the mRNA, protein and activity levels of AA-selective Ca 2 þ -dependent cytosolic PLA 2 (cPLA 2 ), 32, 33 whereas chronic valproate inhibited the activity of an AA-selective acyl-CoA synthetase that is involved in recycling AA back into membrane phospholipids. 27, 34 In contrast to the three antimanic agents, another mood stabilizer, lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine), which is preferred for treating bipolar depression and rapid cycling, neither decreased AA turnover in brain phospholipids of unanesthetized rats 35 nor changed cPLA 2 expression, whereas it decreased transcription and protein of cyclooxygenase (COX)-2. 36 Topiramate (2,3:4,5-bis-Oisopropylidene-b-d-fructopyranose sulfamate), which had been thought effective against BD 37 and shown to reduce hyperactivity in a quinpirole rat model, 38 did not significantly change expression of any of the measured enzymes in the AA cascade, including cPLA 2 , or alter AA or DHA turnover in rat brain phospholipids. 39, 40 Supporting this lack of effect, four double-blind placebo-controlled trials later demonstrated that topiramate was ineffective in BD, 41 and it was withdrawn as a treatment.
A number of antidepressants when administered to bipolar depressed patients cause them to 'switch' to mania more frequently than expected. 2, 3, 42, 43 Because antimanic mood stabilizers when given chronically to rats downregulate brain AA turnover and AA enzymes, we thought it possible that the increased switching tendency caused by some of these antidepressants might be due to their upregulating the brain AA cascade. This hypothesis is consistent with evidence that lamotrigine, which does not upregulate AA turnover but reduces COX-2 expression in rat brain, 35, 36 does not increase switching, whereas fluoxetine, which upregulates AA turnover and cPLA 2 mRNA, protein and activity in rat brain, 44, 45 is reported to do so. 42, 46, 47 To further test the hypothesis, in the present study, we examined brain AA metabolism and expression of brain PLA 2 and COX enzymes in rats treated chronically with two additional antidepressants,
Imipramine, a tricyclic antidepressant, is beneficial for unipolar depression, and is thought to act by inhibiting serotonin and noradrenalin reuptake transporters. At a clinically relevant dose (10 mg kg À1 body weight), imipramine decreases depression scores in rodents, as measured by a variety of tests. [48] [49] [50] [51] Bupropion is thought to act by inhibiting both noradrenalin and dopamine reuptake, but has no significant serotonergic effect. 52 Acute or chronic bupropion given to rats had an antidepressant effect by reducing immobility time in the forced swim test, [53] [54] [55] and improved behavior in another animal model of depression. 56 Because imipramine but not bupropion is reported to increase switching in bipolar depressed patients, 43, 47, [57] [58] [59] we hypothesized that chronic imipramine but not bupropion would increase markers of AA metabolism, including AA turnover in phospholipids and cPLA 2 expression, in rat brain.
Materials and methods

Animals
Chemicals and reagents, including bupropion and imipramine, were purchased from Sigma Chemicals (St Louis, MO, USA) unless otherwise indicated. The study was conducted following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (Publication no. and was approved by the Animal Care and Use Committee of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Animal Care and Use Committee. Male CDF-344 rats, weighing 180-190 g (Charles River Laboratories; Wilmington, MA, USA), were acclimatized for 1 week in an animal facility with controlled temperature, humidity and light cycle, ad libitum access to food (NIH-31) and water. Rats were assigned randomly to an acute or a chronic treatment (imipramine and bupropion) group or to a control group. Chronic drugtreated rats received 10 mg kg À1 day À1 imipramine or 30 mg kg À1 day À1 bupropion dissolved in saline (0.9%) once daily for 21 days intraperitoneally (i.p.), whereas controls received the same volume of saline once daily i.p., also for 21 days. For acute studies (to separate chronic from acute drug action), rats were randomized into three treatment groups that received a single i.p. injection of imipramine (10 mg kg ) or an equivalent volume of saline 3 h before a study.
The chronic dosing regimens for the two drugs are reported to decrease depression scores in rodents, as measured by a variety of behavioral and biochemical tests. [48] [49] [50] [51] 60 On the last day of a dosing regimen, a rat was injected with its appropriate treatment 3 h before its brain was removed for enzyme, protein, prostaglandin E 2 (PGE 2 ) or kinetic analysis. For molecular analysis, 3 h after the last injection, the rat was anesthetized with CO 2 and decapitated. The frontal cortex was rapidly dissected and frozen in 2-methylbutane at À50 1C, then stored at À80 1C until use. For PGE 2 measurements, the rat was lightly anesthetized with sodium pentobarbital (50 mg kg
À1
; Abbott Laboratories, Chicago, IL, USA) and subjected to headfocused microwave irradiation to inactivate enzymes and stop brain metabolism (5.5 kW, 4.8 s; Cober Electronics, Stamford, CT, USA). 61, 62 For the kinetic radiotracer study, the rat was anesthetized with 1-3% halothane, and polyethylene catheters were inserted into the femoral artery and vein as reported. 31 The rat was allowed to recover from surgery for 3 h, with its hindquarters loosely wrapped and taped to a wooden block. During recovery, arterial blood pressure was monitored, and temperature was maintained at 37 1C by means of a rectal probe and a heating element (Indicating Temperature Controller; Yellow Springs Instruments, Yellow Springs, OH, USA). Blood pH, pCO 2 and pO 2 were monitored using a Rapidlab 248 pH/blood gas analyzer (Bayer, East Walpole, MA, USA), and heart rate and blood pressure were analyzed using a CyberSense monitor (Model BPM01 CyQ 302, Nicholasville, KY, USA). Brain lipid extraction and chromatography Total lipids were extracted from frozen plasma and from one brain hemisphere by the method of Folch. 66 Heptadecanoic acid (17:0) was added as an internal standard to plasma before extraction. The extracts were separated by thin layer chromatography on silica gel plates (Whatman, Clifton, NJ, USA). Unesterified fatty acids were separated using a mixture of heptane:diethylether:glacial acetic acid (60:40:2 by volume), 29 and phospholipids (choline glycerophospholipid, ChoGpl; phosphatidylserine, PtdSer; phosphatidylinositol, PtdIns; ethanolamine glycerophospholipid, EtnGpl) were separated in chloroform:-methanol:H 2 O:glacial acetic acid (60:50:4:1 by volume) 67 and identified with unlabeled standards in separate lanes. Phospholipid and standard bands were visualized with 6-p-toluidine-2-naphthalenesulfonic acid (Acros, Fairlawn, NJ, USA) under ultraviolet light. Each band was removed and analyzed for radioactivity by liquid scintillation counting. Phospholipid bands were also individually scraped and 200 ml toluene was added with a known amount of di-17:0-PtdCho for quantification before methylation. Fatty acid methyl esters were formed by heating the phospholipid scrapes in 1% H 2 SO 4 in methanol at 70 1C for 3 h. 68 The methyl esters were separated on a 30 m Â 0.25 mm inner diameter capillary column (SP-2330; Supelco, Bellefonte, PA, USA), using gas chromatography with a flame ionization detector (Model 6890N; Agilent Technologies, Palo Alto, CA, USA). Runs were initiated at 80 1C, with a temperature gradient to 160 1C (10 1C min À1 ) and 230 1C (3 1C min À1 ) in 31 min, and held at 230 1C for 10 min. Peaks were identified by retention times of fatty acid methyl ester standards (Nu-Chek-Prep, Elysian, MN). Fatty acid concentrations (nmol g À1 brain or nmol ml À1 plasma) were calculated by proportional comparison of gas chromatography peak areas to that of the 17:0 internal standard. Tracer identification and separation were performed on fatty acid methyl esters of pooled plasma samples (at the end of the infusion) and pooled brain total lipid extracts as described above. The fatty acid methyl esters were separated as described previously with slight modifications 69 using a high-performance liquid chromatography (HPLC) (Beckman, Fullerton, CA, USA) equipped with an in-line UV/vis detector (l = 242 nm; Gilson, Middleton, WI, USA) and an in-line scintillation counter (b-RAM; IN/US System, Tampa, FL, USA) with a Luna C18 column (Phenomenex, Torrance, CA, USA). Initial conditions were set to a 1 ml min À1 gradient system composed of (A) 100% H 2 O and (B) 100% acetonitrile. The gradient started with 85% B, for 30 min, and then increased to 100% B over 10 min where it was held for 20 min before returning to 85% B over 5 min.
Quantification of labeled and unlabeled acyl-CoA Acyl-CoA species were isolated from the remaining half brain by the method of Deutsch.
70 Weighed brain and a known amount of 17:0-CoA as an internal standard were placed in a 15 ml conical vial before sonication of the brain in 25 mM potassium phosphate. Isopropanol (2 ml) was added to the vial and the homogenate was sonicated again. Saturated ammonium sulfate (0.25 ml) was added and the sample was lightly shaken by hand. Acetonitrile (4 ml) was added and the sample was vortexed for 10 min before centrifugation. The upper phase was extracted and 10 ml of 25 mM potassium phosphate was added. Each sample was run three times through an activated oligonucleotide purification cartridge (Applied Biosystems, Foster City, CA, USA), washed with 10 ml of 25 mM potassium phosphate and eluted with 400 ml isopropanol:1 mM glacial acetic acid (75:25 by volume). Samples were dried under nitrogen and reconstituted in 100 ml isopropanol:1 mM glacial acetic acid (75:25 by volume) for HPLC analysis. Acyl-CoA species were separated using HPLC (Beckman) with a Symmetry C-18, 5 mm column (250 Â 4.6 mm; Waters-Millipore Corp., Milford, MA, USA). Conditions were set to a 1 ml min À1 gradient system composed of (A) 75 mM potassium phosphate and (B) 100% acetonitrile. The gradient started with 44% B, increased to 49% over 25 min and then to 70% over 5 min, remained at 70% for 9 min and returned to 44% over 4 min and was held there for 4 min (end of run). Concentrations of acyl-CoA species and their associated radioactivity were measured using peak area analysis from HPLC chromatograms relative to 17:0-CoA and liquid scintillation counting. These values were used to calculate the specific activities of arachidonoyl-CoA.
Calculations
The model for determining in vivo kinetics of brain fatty acids in rats is described in detail elsewhere. 18, 30 Briefly, unidirectional incorporation coefficients, k i
C]AA, representing incorporation from plasma into brain phospholipid compartments i, were calculated as:
) is radioactivity of brain lipid i at time T = 5 min (time of termination of experiment), t is time after beginning infusion and c pl * (nCi ml
À1
) is the plasma concentration of labeled AA during infusion. Integrals of plasma radioactivity were determined by trapezoidal integration. The synthesis of AA from its dietary precursor linoleic acid (18:2nÀ6) represents less than 0.5% of the plasma AA flux into brain. 71 Thus, net rates of incorporation of non-esterified AA from plasma into brain phospholipid i, J in,i , and from brain arachidonoyl-CoA, J FA,i , were calculated as:
) is the concentration of unlabeled nonesterified AA in plasma. A 'dilution factor' l is defined as the steady-state ratio during [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]AA infusion of specific activity of the brain arachidonoylCoA pool to plasma unesterified AA specific activity,
The steady state is reached within 1 min after infusion begins. 63, 72 The fractional turnover rate of AA within phospholipid i, F FA,i (% h À1 ), is defined as:
Preparation of cytoplasmic and nuclear extracts Cytoplasmic and nuclear extracts were prepared from rat frontal cortex, as previously described. 45 Briefly, the frontal cortex was homogenized in 10 mM HEPES, pH 7.9, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 10 mM KCl, buffer with a protease inhibitor cocktail (Roche, Indianapolis, IN, USA) using a Teflon-glass homogenizer. After adding 0.5% NP-40, five additional strokes were performed. The suspension was incubated for 30 min on ice, and then centrifuged in a microcentrifuge at 13 000 g for 1 h at 4 1C. To the nuclear pellet, solution B (20 mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.4 M NaCl) and a protease inhibitor cocktail (Roche) were added. Tubes were mixed and placed on a small rotatory shaker for 30 min. Finally, the mixture was centrifuged at 13 000 g for 1 h at 4 1C. The supernatant containing the proteins from the nuclear extracts was transferred to a fresh tube. Protein concentrations of cytoplasmic and nuclear extracts were determined using Bio-Rad Protein Reagent (Bio-Rad, Hercules, CA, USA). The composition of extracts from each fraction was confirmed using specific antibodies (data not shown).
Phospholipase A 2 activity and prostaglandin E 2 concentration Supernatants corresponding to the cytosolic fraction were assayed for cPLA 2 activity, using appropriate assay kits (Cayman, Ann Arbor, MI, USA). PGE 2 was extracted according to the method of Radin.
73 A portion of the extract was dried under nitrogen and assayed for PGE 2 using a polyclonal enzyme-linked immunosorbent assay according to the manufacturer's instructions (Oxford Biomedical Research, Product No. EA 02, Oxford, MI, USA).
Western blot analysis
Proteins from cytoplasmic (50 mg) and nuclear (50 mg) extracts were separated on 4-20% SDS-polyacrylamide gels (PAGE) (Bio-Rad). Following SDS-PAGE, the proteins were electrophoretically transferred to a nitrocellulose membrane. Protein blots were incubated overnight at 4 1C in TBS buffer, containing 5% nonfat dried milk and 0.1% Tween-20, with specific primary antibodies (1:1000 dilution) for the group IVA cPLA 2 , group IIA secretory phospholipase A 2 (sPLA 2 ), group VIA calcium-independent phospholipase A 2 (iPLA 2 ), 5 COX-1 (1:1000) (Santa Cruz Biotech, Santa Cruz, CA, USA), activator protein-2a (AP-2a), AP-2b, NFkB p65, p50 and COX-2 (1:1000) (Cell Signaling, Beverly, MA, USA). Protein blots were incubated with appropriate HRP-conjugated secondary antibodies (Cell Signaling) and visualized using a chemiluminescence reaction (Amersham, Piscataway, NJ, USA) on X-ray film (XAR-5, Kodak). Optical densities of immunoblot bands were measured using Alpha Innotech Software (Alpha Innotech, San Leandro, CA, USA) and were normalized to b-actin (Sigma) to correct for unequal loading. All the experiments were carried out three times with 10 independent samples per group. Values are expressed as percent of control.
Total RNA isolation and real time RT-PCR Total RNA and cDNA were prepared as described 27 from frontal cortex and measured by real time quantitative RT-PCR, using the ABI PRISM 7000 sequence detection system (Applied Biosystems). Specific primers and probes for cPLA 2 , purchased from TaqMan gene expression assays (Applied Biosystems), consisted of a 20 Â mix of unlabeled PCR primers and Taqman minor groove binder (MGB) probe (FAM dye-labeled). The fold change in gene expression was determined using the DDC T method. 74 Data are expressed as the relative level of the target gene (cPLA 2 ) in the chronic imipramine-or bupropion-administered animals normalized to the endogenous control (b-globulin) and relative to the control rats (saline injected) (calibrator), as described previously. 32, 45 All the experiments were carried out twice in triplicate with 10 independent samples per group.
Data and statistics
A one-way analysis of variance with Tukey's pairwise post hoc test was used to compare means between rats administered chronic bupropion, chronic imipramine or chronic saline (controls) (SAS 9.1.3, Cary, NC, USA). Statistical significance was taken as Pp0.05. Data are presented as means±standard deviation (s.d.) of independent measurements. Western blot and real time RT-PCR data are presented as means±s.e.m. of independent measurements.
Results
Body weight
Rats chronically administered imipramine weighed 14% and 11% less than did controls or rats given bupropion, respectively (261 ± 14, 224 ± 12, 253 ± 14 g for control, imipramine and bupropion, respectively, P < 0.001). There was no significant difference in body temperature, blood pressure, heart rate, arterial blood pH, pCO 2 or pO 2 between treatment groups and controls.
Plasma and brain fatty acids
As in our previous reports, 28, 35, 40, 44, 62, 64, 75 HPLC separation of fatty acid methyl ester derivatives from total lipid extracts of pooled plasma confirmed that greater than 98% of radioactivity represented labeled AA after 5 min of infusion of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]AA across treatment groups. HPLC separation of fatty acid methyl ester derivatives from pooled brain total lipid extracts also showed that greater than 95% of total brain radioactivity was in the form of [1- 14 C]AA across treatment groups (data not shown). Percent radioactivities from plasma and brain total lipid extracts were comparable between the treated and control rats, and are similar to published data. 28, 35, 40, 44, 62, 64, 75 Chronic or acute imipramine and bupropion did not significantly change the plasma concentration of unlabeled unesterified AA (Table 1) , or of any other measured plasma unesterified fatty acid (data not shown), compared to control. There was no significant difference in the concentration of brain arachidonoyl-CoA or of any other measured acyl-CoA species between treatment groups and controls (Table 1 ). There was no significant difference in the unlabeled esterified fatty acid concentration including AA in brain phospholipids between treatment groups and controls (Table 1) .
Kinetics
The integral of plasma radioactivity (denominator of Equation (1) ) over 5 min. For chronic study, the dilution factor (l) was 0.020 ± 0.006, 0017 ± 0.004, and 0.019 ± 0.006 for controls, imipramine, and bupropion rats, respectively. For acute study, the dilution factor (l) was 0.024±0.006, 0.021±0.006, and 0.024±0.005 for controls, imipramine, and bupropion treated, respectively. For chronic study, rats received saline, 10 mg kg respectively). Chronic imipramine, but not bupropion, increased k i * (Equation (1)) of AA in ChoGpl, PtdIns, EtnGpl and total phospholipids by 24%, 26%, 15% and 21% compared to controls, respectively ( Table 2 ). Chronic imipramine, but not chronic bupropion, increased J in,i (Equation (2)) in ChoGpl, PtdIns, EtnGpl and total phospholipids by 38%, 39%, 29% and 35% compared to controls, respectively ( Table 2) . l (Equation (3)) was not significantly different between imipramine and bupropion-treated rats and controls (Table 3) . Chronic imipramine, but not chronic bupropion, increased J FA,i (Equation (4)) in ChoGpl, PtdSer, PtdIns, EtnGpl and total phospholipids by 71%, 41%, 72%, 58% and 66% compared to controls, respectively ( Table 3 ). The turnover rate of AA (F FA,i , Equation (5)) was significantly higher within brain ChoGpl (80%), PtdSer (38%), PtdIns (63%), EtnGpl (47%) and total phospholipids (59%) in chronic imipramine-treated rats compared to controls (Table 3 ). In contrast, acute imipramine and bupropion did not alter any measured kinetics of AA (Tables 1-3) .
mRNA, protein and activity of cPLA 2 Chronic imipramine, but not bupropion, significantly increased brain cPLA 2 mRNA, protein and phosphorylated protein by 46%, 78% and 103%, respectively, compared to control levels (Figures 1a-c) . Chronic imipramine, but not chronic bupropion, significantly increased cPLA 2 activity by 26% compared to control (Figure 1d ). sPLA 2 and iPLA 2 protein levels did not differ significantly between the groups (Figure 2 ).
Cyclooxygenase protein levels and prostaglandin E 2 concentration Cyclooxygenase-1 and COX-2 protein levels and the concentration of PGE 2 , one of their major metabolites, were not changed significantly after chronic imipramine or bupropion, compared to control (Figure 3 ). cPLA 2 and regulate cPLA 2 transcription. 76, 77 Chronic imipramine, but not chronic bupropion, significantly increased the brain level of AP-2a protein by 48% (Figure 4a) . AP-2b, NF-kB p65 and NF-kB p50 protein levels did not differ significantly between the groups (Figures 4b-d) . The increase in AP-2 may have been responsible in part for the increased cPLA 2 mRNA. ) for 21 days. Data are ratios of optical densities of COX-1 or COX-2 to b-actin, expressed as percent of controls and were compared using a one-way ANOVA with Tukey's post hoc test for multiple comparisons. Data are means±s.e.m., n = 10 rats per group for Western blots, n = 5 or 7 per group for PGE 2 concentration. No significant difference was detected.
Acute effect of imipramine and bupropion Acute imipramine and bupropion did not significantly change brain protein levels of cPLA 2 , sPLA 2 , iPLA 2 , COX-1 or COX-2 compared to the control group ( Figure 5 ).
Discussion
Chronically administered imipramine, but not bupropion, increased AA incorporation and turnover in rat brain phospholipids and increased brain activity, protein, and mRNA levels of AA-selective cPLA 2 78 as well as the level of its transcription factor, AP-2a. Activity and protein levels of sPLA 2 and iPLA 2 were not significantly affected by either drug. None of these changes was observed at 3 h following a single acute injection of imipramine or bupropion, indicating that they reflected the effect of chronic imipramine administration.
These findings, as well as published evidence that drug-induced changes in AA incorporation and turnover in rat brain phospholipids correlate with altered mRNA, protein and activity levels of cPLA 2 , 4,62,79 and expression of its AP-2 transcription factor, suggest that the elevated AA incorporation and turnover rates following chronic imipramine were caused by increased cPLA 2 activity. Similar correlated increases in cPLA 2 and AA turnover follow chronic administration to rats of the antidepressant, fluoxetine. 44 Phosphorylation of cPLA 2 protein by mitogenactivated protein kinase (MAPK) can activate cPLA 2 , 80, 81 and imipramine is reported to activate the MAPK pathway in hippocampus-derived neuronal stem cells. 82 Thus, MAPK activation may have accounted for the increased cPLA 2 phosphorylation by chronic imipramine. The increased cPLA 2 protein caused by chronic imipramine can be ascribed to an increase in cPLA 2 mRNA and increased levels of the transcription factor AP-2a. Earlier studies also reported that increased AP-2 protein and binding activity were associated with increased cPLA 2 mRNA and activity following chronic administration of N-methyl-D-aspartate (NMDA) to rats to produce excitotoxicity. 62, 79 Chronic fluoxetine in rats increased brain cPLA 2 mRNA by increasing the RNA stabilizing protein AUF rather than by increasing AP-2. 45 Neither chronic imipramine nor bupropion changed COX protein or PGE 2 in the rat frontal cortex. Chronic fluoxetine, which increased rat frontal cortex ) for 21 days. Data are ratios of optical densities to b-actin, expressed as percent of controls and were compared using a one-way ANOVA with Tukey's post hoc test for multiple comparisons. Data are means ± s.e.m., n = 10 rats per group. Means within a row not sharing a common superscript are statistically different, P < 0.05. cPLA 2 activity and protein, also did not change brain COX expression or PGE 2 concentration. 44, 45 On the other hand, lithium, carbamazepine and valproic acid, when given chronically to rats, decreased brain COX-2 protein and PGE 2 , and (for lithium and carbamazepine) cPLA 2 expression, and lamotrigine decreased COX-2 transcription. 4, 83, 84 Because chronic imipramine, like chronic fluoxetine, increased rat brain cPLA 2 expression and AA turnover, without changing COX-2 or PGE 2 levels, AA signaling may be related more directly to mood regulation than COX-2 activity or PGE 2 formation. The observations that fluoxetine and imipramine increased AA signaling and cPLA 2 expression, and effects of the antimanic agents in reducing these parameters, also may mean that bipolar mania is correlated with increased release of AA and increased AA metabolism through non-COX pathways.
Imipramine and fluoxetine, but not bupropion, increase the tendency of bipolar depressed patients to 'switch' to mania. 42, 43, 47, [57] [58] [59] 85 Imipramine, which inhibits synaptic reuptake of norepinephrine, serotonin and dopamine, is reported to cause an exceptionally high rate of manic and hypomanic reactions. 43, 57, 86 Bupropion, which inhibits dopamine and norepinephrine but not serotonin reuptake, has a low switch rate, 52, 87 whereas fluoxetine, which primarily inhibits serotonin reuptake, produces a high switch rate.
The data in this paper, taken with published data on fluoxetine administration, suggest that antidepressant agents that increase switching of bipolar depressed patients to a manic state do so by increasing cPLA 2 activity and AA turnover in brain phospholipids. The increased switching tendency may be related to the ability of the drugs to reduce synaptic serotonin uptake and increase serotonin in the synaptic cleft. cPLA 2 activation and AA release from phospholipid can be initiated by activation of postsynaptic serotonergic 5-HT 2A/2C receptors. [6] [7] [8] [9] Studies with additional antidepressants could test this suggestion. Increased brain AA turnover and metabolism may be associated with bipolar mania. In rats that have been subjected to dietary deprivation of nÀ3 polyunsaturated acids, brain cPLA 2 activity, protein and mRNA are upregulated and scores on tests of aggression and depression, BD-like behaviors, are elevated compared with animals on an adequate diet. 88, 89 Further, gene expression of cPLA 2 , sPLA 2 and COX-2 appears increased in postmortem frontal cortex from BD compared to control subjects. Figure 5 Cytosolic phospholipase A 2 (cPLA 2 ) (a), secretory phospholipase A 2 (sPLA 2 ) (b), calcium-independent phospholipase A 2 (iPLA 2 ) (c), cyclooxygenase-1 (COX-1) (d) and cyclooxygenase-1 (COX-2) (e) protein levels in brains of rats acutely administered saline (control), imipramine (10 mg kg À1 ) or bupropion (30 mg kg À1 ). Data are ratios of optical densities of protein to b-actin, expressed as percent of controls and were compared using a one-way ANOVA with Tukey's post hoc test for multiple comparisons. Data are means ± s.e.m., n = 10 rats per group. No significant difference was detected.
